Literature DB >> 34159447

MOF/Hip Fracture Ratio in a Belgian Cohort of Post-menopausal Women (FRISBEE): Potential Impact on the FRAX® Score.

A Mugisha1, P Bergmann2,3, V Kinnard2, L Iconaru4, F Baleanu4, A Charles5, M Surquin6,5, S Rozenberg7, F Benoit6, J J Body3,4,5.   

Abstract

The ratio between major osteoporotic fractures (MOFs) and hip fractures in the Belgian FRAX® tool to predict fractures is currently based on Swedish data. We determined these ratios in a prospective cohort of Belgian postmenopausal women. 3560 women, aged 60-85 years (70.1 ± 6.4 years), were included in a prospective study from 2007 to 2013 and surveyed yearly (FRISBEE). We analyzed the number of validated incident fractures until October 2020 by age and sites and compared the MOFs/hip ratios in this cohort with those from the Swedish databases. We registered 1336 fractures (mean follow-up of 9.1 years). The MOFs/hip ratios extracted from the FRISBEE cohort were 10.7 [95% CI: (5.6-20.5)], 6.4 [4.7-8.7], and 5.0 [3.9-6.5] for women of 60-69, 70-79, and 80-89 years old, respectively. These ratios were 1.7-1.8 times higher for all age groups than those from the Swedish data, which decreased from 6.5 (60-64 years group) down to 1.8 (85-89 age group). The overall MOFs/hip ratio in Frisbee was 6.0 [5.9-6.1], which was higher than any Swedish ratio between 65 and 85 years. Nevertheless, the decrease of the ratios with age paralleled that observed in Sweden. In this Brussels prospective cohort, MOFs/hip ratios were 1.7-1.8 times those observed in Sweden currently used for MOFs prediction in the Belgian FRAX® version. This discrepancy can greatly modify the estimation of the risk of MOFs, which is among the main criteria used to recommend a pharmacological treatment for osteoporosis in several countries.

Entities:  

Keywords:  Aging; FRAX; Fracture prediction; Hip fracture; MOF; Osteoporosis

Year:  2021        PMID: 34159447     DOI: 10.1007/s00223-021-00875-8

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  13 in total

1.  Long-term risk of osteoporotic fracture in Malmö.

Authors:  J A Kanis; O Johnell; A Oden; I Sembo; I Redlund-Johnell; A Dawson; C De Laet; B Jonsson
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

2.  Underevaluation of fractures by self-report: an analysis from the FRISBEE cohort.

Authors:  Felicia Baleanu; Michel Moreau; Virginie Kinnard; Laura Iconaru; Rafik Karmali; Serge Rozenberg; Michel Rubinstein; Marianne Paesmans; Pierre Bergmann; Jean-Jacques Body
Journal:  Arch Osteoporos       Date:  2020-04-22       Impact factor: 2.617

3.  A FRAX® model for the assessment of fracture probability in Belgium.

Authors:  H Johansson; J A Kanis; E V McCloskey; A Odén; J-P Devogelaer; J-M Kaufman; A Neuprez; M Hiligsmann; O Bruyere; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-03-30       Impact factor: 4.507

Review 4.  Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds: A systematic review and meta-analysis.

Authors:  Xuezhi Jiang; Morgan Gruner; Florence Trémollieres; Wojciech Pluskiewicz; Elisabeth Sornay-Rendu; Piotr Adamczyk; Peter F Schnatz
Journal:  Bone       Date:  2017-03-06       Impact factor: 4.398

5.  Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women.

Authors:  Mickaël Hiligsmann; Olivier Bruyère; Olivier Ethgen; Henry-Jean Gathon; Jean-Yves Reginster
Journal:  Bone       Date:  2008-09-10       Impact factor: 4.398

6.  Distribution of clinical risk factors for fracture in a Brussels cohort of postmenopausal women: The FRISBEE study and comparison with other major cohort studies.

Authors:  S I Cappelle; I Ramon; C Dekelver; S Rozenberg; F Baleanu; R Karmali; M Rubinstein; M Tondeur; M Moreau; M Paesmans; P Bergmann; J-J Body
Journal:  Maturitas       Date:  2017-08-24       Impact factor: 4.342

7.  Major osteoporotic to hip fracture ratios in canadian men and women with Swedish comparisons: a population-based analysis.

Authors:  Anna Lam; William D Leslie; Lisa M Lix; Marina Yogendran; Suzanne N Morin; Sumit R Majumdar
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

Review 8.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

Authors:  J A Kanis; A Oden; O Johnell; H Johansson; C De Laet; J Brown; P Burckhardt; C Cooper; C Christiansen; S Cummings; J A Eisman; S Fujiwara; C Glüer; D Goltzman; D Hans; M-A Krieg; A La Croix; E McCloskey; D Mellstrom; L J Melton; H Pols; J Reeve; K Sanders; A-M Schott; A Silman; D Torgerson; T van Staa; N B Watts; N Yoshimura
Journal:  Osteoporos Int       Date:  2007-02-24       Impact factor: 4.507

9.  What is the validity of self-reported fractures?

Authors:  F Baleanu; M Moreau; V Kinnard; L Iconaru; R Karmali; M Paesmans; P Bergmann; J J Body
Journal:  Bone Rep       Date:  2020-05-01

10.  Does the Prediction Accuracy of Osteoporotic Fractures by BMD and Clinical Risk Factors Vary With Fracture Site?

Authors:  L Iconaru; M Moreau; V Kinnard; F Baleanu; M Paesmans; R Karmali; J J Body; P Bergmann
Journal:  JBMR Plus       Date:  2019-10-29
View more
  2 in total

Review 1.  Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.

Authors:  Michaël R Laurent; Stefan Goemaere; Charlotte Verroken; Pierre Bergmann; Jean-Jacques Body; Olivier Bruyère; Etienne Cavalier; Serge Rozenberg; Bruno Lapauw; Evelien Gielen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

2.  Fragility Fractures in Postmenopausal Women: Development of 5-Year Prediction Models Using the FRISBEE Study.

Authors:  Felicia Baleanu; Michel Moreau; Alexia Charles; Laura Iconaru; Rafik Karmali; Murielle Surquin; Florence Benoit; Aude Mugisha; Marianne Paesmans; Michel Rubinstein; Serge Rozenberg; Pierre Bergmann; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.